PainReform (NASDAQ:PRFX – Get Free Report)‘s stock had its “hold” rating reaffirmed by equities researchers at Maxim Group in a research note issued on Thursday, Benzinga reports.
PainReform Stock Performance
Shares of NASDAQ:PRFX traded down $0.04 on Thursday, hitting $0.70. The stock had a trading volume of 7,151 shares, compared to its average volume of 166,450. The firm’s 50 day moving average price is $0.56 and its 200-day moving average price is $0.63. PainReform has a twelve month low of $0.53 and a twelve month high of $20.16. The company has a market capitalization of $406,058.00, a price-to-earnings ratio of -0.02 and a beta of 0.54.
PainReform (NASDAQ:PRFX – Get Free Report) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.40) EPS for the quarter.
Institutional Investors Weigh In On PainReform
About PainReform
PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.
Recommended Stories
- Five stocks we like better than PainReform
- What Are Dividend Achievers? An Introduction
- A $1.75 Billion Gamble: Can Lucid Ignite Growth?
- ETF Screener: Uses and Step-by-Step Guide
- The Rally in Lockheed Martin and RTX Can Continue: Here’s Why
- How to Use the MarketBeat Dividend Calculator
- 3 Undervalued Technology Stocks With Big Rebound Potential
Receive News & Ratings for PainReform Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PainReform and related companies with MarketBeat.com's FREE daily email newsletter.